Date Title Description PDF
12 Apr 2021 On business and financial situation The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. Download
02 Mar 2021 On business and financial situation The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
02 Mar 2021 On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
24 Feb 2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download

Pages

Date Title Description PDF
12 Mar 2024 On business and financial situation ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies Download
08 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 1 March and 7 March 2024 Download
07 Mar 2024 On corporate transactions ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives  Download
01 Mar 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 23 February and 29 February 2024 Download
27 Feb 2024 Annual Financial Reports and Audit Reports The Company submits the 2023 Annual Financial Report  Download

Pages

Date Title Description PDF
06 Apr 2017 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the first quarter of 2017 Download
13 Mar 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to its biosimilar of Enoxaparin Download
07 Mar 2017 Otros sobre negocio y situación financiera ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome Download
16 Feb 2017 Otros sobre Gobierno Corporativo The Company informs about the agreements adopted by the Board of Directors Download
16 Feb 2017 Informe anual de remuneraciones de los consejeros ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors Download

Pages